MedPath

Prospective Long-term Evaluation of the Efficacy and Safety of Calistar S for Transvaginal Pelvic Organ Prolapse Repair

Not Applicable
Active, not recruiting
Conditions
Pelvic Organ Prolapse
Interventions
Device: Transvaginal mesh for anterior pelvic organ prolapse repair
Registration Number
NCT03821142
Lead Sponsor
Promedon
Brief Summary

Prospective long-term evaluation of the performance and safety of Calistar S for transvaginal pelvic organ prolapse repair in women with anterior POP with or without apical vaginal involvement

Detailed Description

Calistar S Single Incision Pelvic Organ Prolapse (POP) Repair System is intended for transvaginal reestablishment and reinforcement of the physiologic anatomy of the female pelvic floor in non-fertile women with anterior pelvic organ prolapse with or without apical vaginal wall involvement in both, recurrent pelvic organ prolapse and primary pelvic organ prolapse when other surgical procedures are expected to fail (i.e. complex primary prolapse).

The treatment kit consists of the lightweight mesh, two single-use introducers and 3 tissue anchoring system (TAS) anchors for fixation to the sacrospinous ligament. The product is approved in accordance with the CE Directive 93/42/EEC.

The utilization of synthetic implants in POP repair became increasingly popular in the last decade. The cumulative success rate of synthetic implants in anterior compartment repair is as high as up to 93%.However, meshes have been recently scrutinized due to high adverse event reporting after unreflected utilization of meshes which raised concerns of patients safety; furthermore taking into account the complexity of adverse event mesh management. This led to a vanishing of various meshes in transvaginal POP repair. Nevertheless, the further development of light weight meshes, the experience of the surgeon and the assessment and patients selection are well known factors reducing the rate of adverse events significantly.

Therefore, in the current trial the efficacy and safety of calistar S in a highly selected patient population will be evaluated.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Female
Target Recruitment
180
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Calistar STransvaginal mesh for anterior pelvic organ prolapse repairSingle arm cohort trial
Primary Outcome Measures
NameTimeMethod
Number of Patients with Cure of pelvic organ prolapse24 months

Number of patients accomplishing the composite endpoint after 24 months including anatomic, subjective and retreatment components

Secondary Outcome Measures
NameTimeMethod
Patient subjective evaluation of POP severity according the Global Impression of SeverityBaseline

Evaluation of severity categorization by assing the Patient Global Impression of Severity of each patient at Baseline. Score. 4 Likert scale, from no impact to very much impact. A

Change of quality of life according the EQ-5L-5D in comparison between baseline and follow-upBaseline, 6 weeks and 6, 12, 24, 36, 48, 60 months

Evaluation of Quality of life assessed by the EQ-5L-5D and evaluation of differences between Baseline and Follow-Up of each patient regarding health related Quality of life. Two scores: a) 5 Likert scale from no problems to extreme problems. b) self administered quality of life in scale 0 - 100, the higher the score the better the quality of life.

Anatomical success according the number of patients with anterior vaginal wall at or above the hymen and no decent of apical vaginal wall at or greater than half of the total vanilla lengths6 weeks and 6, 12, 24, 36, 48, 60 months

Anatomical success defined by the number of patients with the anterior vaginal wall at or above the hymen (Aa and Ba ≤ 0 ) and separately no decent of apical vaginal wall at or greater than half of the total vaginal lengths (C \< -½ TVL).

Number of patients with necessity of repeated surgery due to recurrent anterior or apical Number of patients with Repeat surgery due to symptomatic recurrence of anterior or apical POP6 weeks and 6, 12, 24, 36, 48, 60 months

Number of patients with necessity of repeated surgery due to recurrent anterior or apical POP.

Safety of Calistar S according the number of adverse eventsintraoperative, postoperative, 6 weeks, and 6, 12, 24, 36, 48, 60 months and unscheduled visits

Safety of Calistar S according the assessment of total amount of adverse events

Exposure and anatomical-failure free survival12, 24, 36, 48, 60 months

Estimation of exposure- and anatomical-failure free survival according Kaplan meier

Number of patients with further surgery for stress urinary incontinence6 weeks and 6, 12, 24, 36, 48, 60 months

To assess the number of patients with further surgery for stress urinary incontinence.

Change of urinary incontinence according the ICIQ-UI-Sf in comparison between baseline and follow-upBaseline 6 weeks and 6, 12, 24, 36, 48, 60 months

The international Consultation of Incontinence Questionnaire - Urinary Incontinence - Short Form (ICIQ-UI-SF) is a validated questionnaire to asses urinary incontinence. Score 0-21, overall score with greater values indicating increased symptom severity

Change of overactive bladder symptoms according the ICIQ-OAB in comparison between baseline and follow-upBaseline 6 weeks and 6, 12, 24, 36, 48, 60 months

The International Consultation of Incontinence Questionnaire - Overacitve bladder (ICIQ-OAB) is a validated questionnaire.. 0-16 overall score with greater values indicating increased symptom severity

Change of prolapse specific quality of life according the validated Questionnaire Prolapse quality of life questionnaire in comparison between baseline and follow-upBaseline, 6 weeks and 6, 12, 24, 36, 48, 60 months

Differences between Baseline and Follow-Up result of the questionnaire of each patient regarding Quality of life and the correlating domains will be evaluated. P-QoL, Score: 0-100, the higher the score, the higher the impact of prolapse symptoms and the lower quality of life.

Change of sexual life according the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire in comparison between Baseline and follow-upBaseline, 6 weeks and 6, 12, 24, 36, 48, 60 months

Differences between Baseline and Follow-Up result of each patient regarding Sexual life and the correlating domains will be evaluated. PISQ-IR, Score: 0-100, the higher the score, the higher the impact of prolapse symptoms and the higher the impact on sexual life.

Change of pain according Visual Analog Scale of Pain in comparison between baseline, postoperative and follow-upBaseline, 24-48h postoperatively, 6 weeks and 6, 12, 24, 36, 48, 60 months

Differences of pain-evaluation between Baseline and Follow-Up of each patient will be evaluated. Wong Baker Pain Scale, Score: 0 - 10, The higher the score, the higher the pain.

Patients subjective evaluation of satisfaction with surgery according the Patient Global Impression of Improvement6 weeks and 6, 12, 24, 36, 48, 60 months

Evaluation of the improvement of POP after the operation assed by the Patient Global Impression of Improvement of each patient. PGI-I, Score: 7 Likert scale from: very much better to very much worse,

Cure in short-, mid-, and longterm follow-up6 weeks and 6, 12, 36, 48, 60 months

Number of patients accomplishing the composite outcome at remaining follow-up times

Trial Locations

Locations (6)

Helios Hospital Erfurt, Department of gynaecology

🇩🇪

Erfurt, Thüringen, Germany

St. Hedwig Hospital

🇩🇪

Berlin, Germany

Evangelic Diakonie Hospital

🇩🇪

Freiburg, Germany

St. Elisabeth-Hospital Leipzig

🇩🇪

Leipzig, Germany

Hospital Tettnang

🇩🇪

Tettnang, Germany

University Hospital Tübingen

🇩🇪

Tübingen, Germany

© Copyright 2025. All Rights Reserved by MedPath